Aurigene reports results of AUR101 in phase-II study in patients with moderate-to-severe psoriasis
The Indus-III study met its primary endpoint of PASI-75 response at 12 weeks at the 400 mg BID dose, when compared to placebo
Recover your password.
A password will be e-mailed to you.
Recover your password.
A password will be e-mailed to you.